Drug discovery in the extracellular matrix

Drug Discovery Today

Volumn 13, Issue 15-16, 2008, Pages 685-694

  Huxley Jones, Julie ^a   Foord, Steven M ^a   Barnes, Michael R ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CGS 27023A; DX 2400; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR;

DRUG INDICATION; DRUG RESEARCH; DRUG TARGETING; EXTRACELLULAR MATRIX; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; REVIEW;

ANIMALS; DRUG DISCOVERY; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 48149115209     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.05.005     Document Type: Review

References (65)

1. Lukashev M.E., and Werb Z. ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol. 8 (1998) 437-441
2. Zacchigna L., et al. Emilin1 links TGF-beta maturation to blood pressure homeostasis. Cell 124 (2006) 929-942
3. Heino J. The collagen family members as cell adhesion proteins. BioEssays 29 (2007) 1001-1010
4. Aumailley M., and Smyth N. The role of laminins in basement membrane function. J. Anat. 193 (1998) 1-21
5. Timpl R., et al. Fibulins: a versatile family of extracellular matrix proteins. Nat. Rev. Mol. Cell Biol. 4 (2003) 479-489
6. Bosman F.T., and Stamenkovic I. Functional structure and composition of the extracellular matrix. J. Pathol. 200 (2003) 423-428
7. Gelse K., Poschl E., and Aigner T. Collagens - structure, function and biosynthesis. Adv. Drug Deliv. Rev. 55 (2003) 1531-1546
8. Sternlicht M.D., and Werb Z. How matrix metalloproteinases regulate cell behaviour. Annu. Rev. Cell. Dev. Biol. 17 (2001) 463-516
9. Schenk S., and Quaranta V. Tales from the crypt(ic) sites of the extracellular matrix. Trends Cell Biol. 13 (2003) 366-375
10. Johnson P.R.A., et al. Extracellular matrix proteins modulate asthmatic airway smooth muscle cell proliferation via an autcrine mechanism. J. Allergy Clin. Immunol. 113 (2004) 690-696
11. Ria R., et al. AlphaVbeta3 integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica 98 (2002) 836-845
12. Haas C.A., et al. Role for reelin in the development of granule cell dispersion in temporal lobe epilepsy. J. Neurosci. 22 (2002) 5797-5802
13. Abifadel M., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34 (2003) 154-156
14. Mosnier J.F., et al. ADAM15 upregulation and interaction with multiple binding partners in inflammatory bowel disease. Lab. Invest. 86 (2006) 1064-1073
15. Barresu R., and Campbell K.P. Dystroglycan: from biosynthesis to pathogenesis of human disease. J. Cell Sci. 119 (2006) 199-207
16. Roach H.I., et al. Pathobiology of osteoarthritis: pathomechanisms and potential therapeutic targets. Curr. Drug Target. 8 (2007) 271-282
17. Costa E., et al. REELIN and schizophrenia: a disease at the interface of the genome and the epigenome. Mol. Intervent. 2 (2007) 47-57
18. Farb A., et al. Extracellular matrix changes in stented human coronary arteries. Circulation 110 (2004) 940-947
19. Furlan M., et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 89 (1997) 3097-3103
20. Lal H., et al. Integrins: novel therapeutic targets for cardiovascular diseases. Cardiovasc. Hematol. Agents Med. Chem. 5 (2007) 109-132
21. Hu J., et al. Matrix metalloproteases inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 6 (2007) 480-498
22. Nichols S.A., et al. Early evolution of animal cell signalling and adhesion genes. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 12451-12456
23. Ewan R., et al. The integrins of the urochordate Ciona intestinalis provide novel insights into the molecular evolution of the vertebrate integrin family. BMC Evol. Biol. 5 (2005) 31
24. Huxley-Jones J., et al. The characterisation of six ADAMTS proteases in the basal chordate Ciona intestinalis provides new insights into the vertebrate ADAMTS family. Int. J. Biochem. Cell Biol. 37 (2005) 1838-1845
25. Huxley-Jones J., et al. The evolution of the vertebrate metzincins, insights from Ciona intestinalis and Danio rerio. BMC Evol. Biol. 7 (2007) 63
26. Huxley-Jones J., Robertson D.L., and Boot-Handford R.P. On the origins of the extracellular matrix in vertebrates. Matrix Biol. 26 (2007) 2-11
27. Puente X.S., et al. A genomic view of the complexity of mammalian proteolytic systems. Biochem. Soc. Trans. 33 (2005) 331-334
28. Hopkins A.L., and Groom C.R. The druggable genome. Nat. Rev. Drug Discov. 1 (2002) 727-730
29. Vasiljeva O., et al. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr. Pharm. Des. 13 (2007) 387-403
30. Overall C.M., and Kleifeld O. Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 6 (2006) 239-277
31. McQuibban G.A., et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell derived factor-1. J. Biol. Chem. 276 (2001) 43503-43508
32. Kong H.J., and Mooney D.J. Microenvironmental regulation of biomacromolecular therapies. Nat. Rev. Drug Discov. 6 (2007) 455-463
33. Yong V.W., et al. Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci. 2 (2001) 502-511
34. Poole A.R., et al. Composition and structure of articular cartilage: a template for tissue repair. Clin. Orthop. Relat. Res. 391 (2001) S26-S33
35. Neeves K.B., et al. Dilation and degradation of the brain extracellular matrix enhances penetration of infused polymer nanoparticles. Brain Res. 1180 (2007) 121-132
36. Lukacova V., et al. Similarity of binding sites of human matrix metalloproteinases. J. Biol. Chem. 279 (2004) 14194-14200
37. Levitt N.C., et al. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor MMI270 (CGS27023A) in patients with advanced solid cancer. Clin. Cancer Res. 7 (2001) 1912-1922
38. Skiles J.W., et al. The design, structure and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med. Chem. 8 (2001) 425-474
39. Page-McCaw A., et al. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 8 (2007) 221-233
40. Hajduk P.J., et al. Predicting protein druggability. Drug Discov. Today 10 (2005) 1675-1682
41. Russ A.P., and Lampel S. The druggable genome: an update. Drug Discov. Today 10 (2005) 1607-1610
42. Sakharkar M.K., et al. Druggability of human disease genes. Int. J. Biochem. Cell Biol. 39 (2007) 1156-1164
43. Overington J.P., et al. How many drug targets are there?. Nat. Rev. Drug Discov. 5 (2006) 993-996
44. Hardisty R., et al. A defect of platelet aggregation associated with an abnormal distribution of glycoprotein IIb-IIIa complexes within the platelet: the cause of a lifelong bleeding disorder. Blood 80 (1992) 696-708
45. Hayashi Y.K., et al. Mutations in the integrin alpha-7 gene cause congenital myopathy. Nat. Genet. 19 (1998) 94-97
46. Georges-Labouesse E., et al. Absence of integrin alpha-6 leads to epidermolysis bullosa and neonatal death in mice. Nat. Genet. 13 (1996) 370-373
47. Lin G., and Stern R. Plasma hyaluronidase (HYAL-1) promotes tumor cell cycling. Cancer Lett. 163 (2001) 95-101
48. Rogers D.F. Mucoactive agents for airway mucus hypersecretory diseases. Respir. Care 52 (2007) 1176-1193
49. Meyer A., et al. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr. Pharm. Des. 12 (2006) 2723-2747
50. Chellaiah M.A., and Hruska K.A. The integrin alpha V beta 3 and CD44 regulate the actions of osteopontin on osteoclast motility. Calc. Tissue Int. 72 (2003) 197-205
51. Seemayer C.A., et al. Rheumatoid arthritis: new developments in the pathogenesis with special reference to synovial fibroblasts. Zeitschrift fur Rheumatologie 60 (2001) 309-318
52. Srivatsa S.S., et al. Selective alpha(v)beta(3) integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: Evidence for the functional importance of integrin alpha(v)beta(3) and osteopontin expression during neointima formation. Cardiovasc. Res. 36 (1997) 408-428
53. Hammes H.P., et al. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat. Med. 2 (1996) 529-533
54. Lu D., et al. Integrin binding characteristics of the disintegrin-like domain of ADAM15. Thromb. Haemost. 96 (2006) 642-651
55. Charruer L., et al. ADAM15/metargidin mediates homotypic aggregation of human T lymphocytes and heterotypic interactions of T lymphocytes with intestinal epithelial cells. J. Biol. Chem. 282 (2007) 16948-16958
56. Rawlings N.D., et al. MEROPS: the peptidase database. Nucleic Acids Res. 36 (2008) D320-D325
57. Dallas S.J., et al. Proteolysis of latent transforming growth factor-b (TGF-b) binding protein-1 by osteoclasts. J. Biol. Chem. 277 (2002) 21352-21360
58. Orend G., and Chiquet-Erismann R. Tenascin-C induced signaling in cancer. Cancer Lett. 244 (2006) 143-163
59. Franzke C.-W., et al. Transmembrane collagen XVII, an epithelial adhesion protein, is shed from the cell surface by ADAMs. EMBO J. 21 (2002) 5026-5035
60. Ge G., and Greenspan D.S. BMP1 controls TGFb1 activation via cleavage of latent TGFb-binding protein. J. Cell Biol. 175 (2006) 111-120
61. Hills R., et al. Identification of an ADAMTS-4 cleavage motif using phage display leads to the development of fluorogenic peptide substrates and reveals Matrilin-3 as a novel substrate. J. Biol. Chem. 282 (2007) 11101-11109
62. Orth A.P., et al. The promise of genomics to identify novel therapeutic targets. Exp. Opin. Therap. Targets 8 (2004) 587-596
63. Thompson J.D., et al. The CLUSTALX windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 24 (1997) 4877-4882
64. Felsenstein J. PHYLIP (Phylogeny Inference Package) (2005), Department of Genome Sciences, University of Washington
65. Huelsenbeck J.P., and Ronquist F. MRBAYES: Bayesian inference of phylogenetic trees (2000), Department of Biology, University of Rochester